The project by MB Therapeutics has been designated a winner of the France 2030 call for projects, a strategic national program aimed at supporting breakthrough innovations in priority sectors, including healthcare innovation. This distinction is accompanied by major financial support that will amplify the development of our next-generation medicine and anchor our industrial growth in France and worldwide.

Strategic support to accelerate the development of next-generation medicine

This funding is part of France 2030's commitment to supporting innovative, high-value health solutions with a strong impact on French health sovereignty. For MB Therapeutics, this national recognition constitutes a decisive accelerator in the development of our next-generation medicine, based on an ambitious approach.

Thanks to this support, we will:

• Strengthen our R&D program, with a scale-up of our scientific innovation capabilities.

• Accelerate the market launch of our turnkey solution for personalized medicine manufacturing. 

• Accelerate the development of our innovative high-value-added products, notably our pharmaceutical inks, to meet the specific needs of patients. 

• Strengthen our collaboration with public and regional partners to structure sustainable production. 

   

France 2030: a powerful lever to transform the healthcare sector in France

The France 2030 program, led by the State and implemented regionally, aims to foster the emergence of breakthrough technologies in strategic sectors. In this context, MB Therapeutics has been selected as a regional winner of the "Innovation Projects" call for projects, a strong recognition of the relevance of our technological approach rooted in the region.

We are thus benefiting from €500,000 in public funding, intended to support the acceleration of our R&D program, the industrialization of our therapeutic inks, and the structuring of our production site in Montpellier. This support reinforces the momentum generated by our €2 million fundraising and marks a key step towards our goal: making secure, local, and personalized medicine production accessible in pharmacies.

Recognition of our vision and commitment to innovation

This funding represents a major recognition of the quality of our research, the relevance of our model, and the daily commitment of our teams to providing concrete answers to public health challenges.

Being supported under the France 2030 plan is a seal of credibility that validates our scientific and strategic choices, and gives us the means to go faster and further in the mission of MB Therapeutics.